Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Nov 16, 2018)
Applauds the growth in research and development into new therapies for rare diseases and the resulting number of FDA-approved therapies for those living with rare diseases, and affirms the need to continue supporting such research and development.
Recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.
What just happenedNov 16, 2018
Referred to the House Committee on Energy and Commerce.
Who’s behind it
- Introduced in HouseNov 16, 2018
- Nov 16, 2018IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Nov 16, 2018IntroReferralIntro-H
Introduced in House
- Nov 16, 2018IntroReferral1000
Introduced in House